BC
CAPR icon

Broadfin Capital’s Capricor Therapeutics CAPR Stock Holding History

Broadfin Capital’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-11,800
Closed -$596K – 92
2015
Q2 		$596K Sell
11,800
-58,788
-83% -$3.69M 0.03% 92
2015
Q1 		$4.87M Buy
+70,588
New +$6.09M 0.38% 64

Other funds holding CAPR

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CFN
Cordasco Financial Network Naples, Florida $138M AUM 10.5% 1-Year Est. Return

Broadfin Capital's CAPR Position: Q3 2015 in Review

Broadfin Capital sold out of Capricor Therapeutics (CAPR) in Q3 2015, closing a stake of 11,800 shares — an estimated $596K sold.

Broadfin Capital first reported a position in CAPR in Q1 2015 and held it in 2 quarters. The position peaked at $4.87M in Q1 2015. 15 funds tracked by Wall St. Rank hold CAPR as of Q3 2015.

  • Broadfin Capital reported no remaining Capricor Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Broadfin Capital sold 11,800 Capricor Therapeutics shares in Q3 2015, an estimated $596K.
  • Broadfin Capital first reported a position in Capricor Therapeutics in Q1 2015 and held it in 2 quarters.
  • Broadfin Capital's Capricor Therapeutics position peaked at $4.87M in Q1 2015.
  • 15 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2015.

Based on Broadfin Capital's 13F filing for Q3 2015, filed 16 Nov 2015.